FDA to pharma companies: Using CRO Synapse's studies 'unacceptable'
The FDA is not holding punches against India-based CRO Synapse, saying that studies conducted by the group are “unacceptable” due to data integrity issues and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.